GlaxoSmithKline Launches Ulcerative Colitis Study
News: Belgium-based Galapagos announced that the UK-based drugmaker GlaxoSmithKline (GSK) plans to initiate an exploratory Phase 2 study with GSK2586184 (formerly GLPG0778) molecule in ulcerative colitis patients. This is the third indication for the investigational molecule, in addition to psoriasis and lupus. GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos' partnership with GSK. The Phase 2 studies with GSK2586184 in ulcerative colitis, psoriasis, and lupus are scheduled to be completed in November 2014, March 2014 and November 2015 respectively.